A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Matthews, P. | - |
dc.contributor.author | Alpert, M. | - |
dc.contributor.author | Rahav, G. | - |
dc.contributor.author | Rill, D. | - |
dc.contributor.author | Zito, E. | - |
dc.contributor.author | Gardiner, D. | - |
dc.contributor.author | Pedersen, R. | - |
dc.contributor.author | Babinchak, T. | - |
dc.contributor.author | McGovern, P.C. | - |
dc.contributor.author | Armstrong, P. | - |
dc.contributor.author | Bailey, C. | - |
dc.contributor.author | Berbel, G. | - |
dc.contributor.author | Bernstein, J. | - |
dc.contributor.author | Bordon, J. | - |
dc.contributor.author | Bruno-Murtha, L.A. | - |
dc.contributor.author | Caprioli, R. | - |
dc.contributor.author | Casey, K. | - |
dc.contributor.author | Chiang, T. | - |
dc.contributor.author | Churukian, A. | - |
dc.contributor.author | Flynn, W. | - |
dc.contributor.author | Graham, D. | - |
dc.contributor.author | Hao, Z. | - |
dc.contributor.author | Kalassian, K. | - |
dc.contributor.author | Kohler, R. | - |
dc.contributor.author | Lee, J. | - |
dc.contributor.author | Leeds, W. | - |
dc.contributor.author | Lucasti, C. | - |
dc.contributor.author | Malanoski, G. | - |
dc.contributor.author | Ko, T. | - |
dc.contributor.author | Minnaganti, V. | - |
dc.contributor.author | Mogyoros, M. | - |
dc.contributor.author | Morgan, B. | - |
dc.contributor.author | Moss, C. | - |
dc.contributor.author | Muluk, S. | - |
dc.contributor.author | Murthy, R. | - |
dc.contributor.author | O'Riordan, W. | - |
dc.contributor.author | Pien, F. | - |
dc.contributor.author | Polk, H. | - |
dc.contributor.author | Augustinsky, J.B. | - |
dc.contributor.author | Salvaggio, M. | - |
dc.contributor.author | Smith, L. | - |
dc.contributor.author | Smith, R. | - |
dc.contributor.author | Scott, Stienecker R. | - |
dc.contributor.author | Suh, B. | - |
dc.contributor.author | Vazquez, J. | - |
dc.contributor.author | Weiland, D.E. | - |
dc.contributor.author | Wessolossky, M. | - |
dc.contributor.author | Zenilman, J. | - |
dc.contributor.author | Abraham, C. | - |
dc.contributor.author | Nathan, R. | - |
dc.contributor.author | Sanchez, P. | - |
dc.contributor.author | Baird, I. | - |
dc.contributor.author | Callahan, C. | - |
dc.contributor.author | Schrock, C.G. | - |
dc.contributor.author | Lau, W. | - |
dc.contributor.author | Bochan, M.R. | - |
dc.contributor.author | Somero, M. | - |
dc.contributor.author | Klein, S.R. | - |
dc.contributor.author | Bellows, C. | - |
dc.contributor.author | D'Hooghe, A. | - |
dc.contributor.author | Ceulemans, F. | - |
dc.contributor.author | Gaillat, J. | - |
dc.contributor.author | Garo, B. | - |
dc.contributor.author | Eckmann, C. | - |
dc.contributor.author | Haier, J. | - |
dc.contributor.author | Suter, F. | - |
dc.contributor.author | Bertani, A. | - |
dc.contributor.author | Acin, F. | - |
dc.contributor.author | Jim?nez-Mej?as, M.E. | - |
dc.contributor.author | Blanes, I. | - |
dc.contributor.author | Regueiro, D.S. | - |
dc.contributor.author | Cakir, N. | - |
dc.contributor.author | Saba, R. | - |
dc.contributor.author | Giladi, M. | - |
dc.contributor.author | Kanj-Sharara, S. | - |
dc.contributor.author | Ahmed, al Thaqafi A.O. | - |
dc.contributor.author | Ng, W.-M. | - |
dc.contributor.author | Burd, A. | - |
dc.contributor.author | Kurlekar, U. | - |
dc.contributor.author | Rao, N.R. | - |
dc.contributor.author | Devarajan, T. | - |
dc.contributor.author | Choi, J. | - |
dc.contributor.author | Kim, Y. | - |
dc.contributor.author | Pai, H. | - |
dc.contributor.author | Park, Y.-S. | - |
dc.contributor.author | Kumar, S. | - |
dc.contributor.author | Chow, T.S. | - |
dc.contributor.author | Crisostomo, A. | - |
dc.contributor.author | Erasmo, A. | - |
dc.contributor.author | Low, J. | - |
dc.contributor.author | Basson, | - |
dc.contributor.author | Breedt, J. | - |
dc.contributor.author | Matthews, | - |
dc.contributor.author | Ross, D.P. | - |
dc.contributor.author | Lin, H.-H. | - |
dc.contributor.author | Liao, C.-H. | - |
dc.contributor.author | Kung, H.-C. | - |
dc.contributor.author | Chinswangwatanakul, V. | - |
dc.contributor.author | Malathum, K. | - |
dc.contributor.author | Tantawichien, T. | - |
dc.contributor.author | Sergio, Ricardo Filho Penteado | - |
dc.contributor.author | Cardoso, F. | - |
dc.contributor.author | Gomez, R.F. | - |
dc.contributor.author | Velazquez, D.F. | - |
dc.contributor.author | Tinoco-Favila, J.C. | - |
dc.contributor.author | Poirier, A. | - |
dc.contributor.author | Valiquette, L. | - |
dc.contributor.author | Weiss, K. | - |
dc.contributor.author | Grimard, D. | - |
dc.contributor.author | Embil, J.M.A. | - |
dc.contributor.author | Sanche, S.E. | - |
dc.contributor.author | Smith, K. | - |
dc.contributor.author | Chouinard, S. | - |
dc.contributor.author | Dolc?, P. | - |
dc.date.accessioned | 2022-07-16T13:04:13Z | - |
dc.date.available | 2022-07-16T13:04:13Z | - |
dc.date.created | 2021-05-11 | - |
dc.date.issued | 2012-11 | - |
dc.identifier.issn | 1471-2334 | - |
dc.identifier.uri | https://scholarworks.bwise.kr/hanyang/handle/2021.sw.hanyang/164374 | - |
dc.description.abstract | Background: Complicated skin and skin structure infections (cSSSIs) frequently result in hospitalization with significant morbidity and mortality.Methods: In this phase 3b/4 parallel, randomized, open-label, comparative study, 531 subjects with cSSSI received tigecycline (100 mg initial dose, then 50 mg intravenously every 12 hrs) or ampicillin-sulbactam 1.5-3 g IV every 6 hrs or amoxicillin-clavulanate 1.2 g IV every 6-8 hrs. Vancomycin could be added at the discretion of the investigator to the comparator arm if methicillin-resistant Staphylococcus aureus (MRSA) was confirmed or suspected within 72 hrs of enrollment. The primary endpoint was clinical response in the clinically evaluable (CE) population at the test-of-cure (TOC) visit. Microbiologic response and safety were also assessed. The modified intent-to-treat (mITT) population comprised 531 subjects (tigecycline, n = 268; comparator, n = 263) and 405 were clinically evaluable (tigecycline, n = 209; comparator, n = 196).Results: In the CE population, 162/209 (77.5%) tigecycline-treated subjects and 152/196 (77.6%) comparator-treated subjects were clinically cured (difference 0.0; 95% confidence interval [CI]: -8.7, 8.6). The eradication rates at the subject level for the microbiologically evaluable (ME) population were 79.2% in the tigecycline treatment group and 76.8% in the comparator treatment group (difference 2.4; 95% CI: -9.6, 14.4) at the TOC assessment. Nausea, vomiting, and diarrhea rates were higher in the tigecycline group.Conclusions: Tigecycline was generally safe and effective in the treatment of cSSSIs.Trial registration: ClinicalTrials.gov NCT00368537. | - |
dc.language | 영어 | - |
dc.language.iso | en | - |
dc.publisher | BMC Med Central | - |
dc.title | A randomized trial of tigecycline versus ampicillin-sulbactam or amoxicillin-clavulanate for the treatment of complicated skin and skin structure infections | - |
dc.type | Article | - |
dc.contributor.affiliatedAuthor | Pai, H. | - |
dc.identifier.doi | 10.1186/1471-2334-12-297 | - |
dc.identifier.scopusid | 2-s2.0-84868633430 | - |
dc.identifier.wosid | 000314232400001 | - |
dc.identifier.bibliographicCitation | BMC Infectious Diseases, v.12, pp.1 - 9 | - |
dc.relation.isPartOf | BMC Infectious Diseases | - |
dc.citation.title | BMC Infectious Diseases | - |
dc.citation.volume | 12 | - |
dc.citation.startPage | 1 | - |
dc.citation.endPage | 9 | - |
dc.type.rims | ART | - |
dc.type.docType | Article | - |
dc.description.journalClass | 1 | - |
dc.description.isOpenAccess | Y | - |
dc.description.journalRegisteredClass | scie | - |
dc.description.journalRegisteredClass | scopus | - |
dc.relation.journalResearchArea | Infectious Diseases | - |
dc.relation.journalWebOfScienceCategory | Infectious Diseases | - |
dc.subject.keywordPlus | SOFT-TISSUE INFECTIONS | - |
dc.subject.keywordPlus | STAPHYLOCOCCUS-AUREUS | - |
dc.subject.keywordPlus | IN-VITRO | - |
dc.subject.keywordPlus | ANTIMICROBIAL AGENTS | - |
dc.subject.keywordPlus | PRACTICE GUIDELINES | - |
dc.subject.keywordPlus | DISEASES SOCIETY | - |
dc.subject.keywordPlus | VANCOMYCIN | - |
dc.subject.keywordPlus | EFFICACY | - |
dc.subject.keywordPlus | GAR-936 | - |
dc.subject.keywordPlus | PHASE-3 | - |
dc.subject.keywordAuthor | CSSSI | - |
dc.subject.keywordAuthor | Glycylcycline | - |
dc.subject.keywordAuthor | Skin and skin structure infection | - |
dc.subject.keywordAuthor | Tigecycline | - |
dc.identifier.url | https://bmcinfectdis.biomedcentral.com/articles/10.1186/1471-2334-12-297 | - |
Items in ScholarWorks are protected by copyright, with all rights reserved, unless otherwise indicated.
222, Wangsimni-ro, Seongdong-gu, Seoul, 04763, Korea+82-2-2220-1365
COPYRIGHT © 2021 HANYANG UNIVERSITY.
Certain data included herein are derived from the © Web of Science of Clarivate Analytics. All rights reserved.
You may not copy or re-distribute this material in whole or in part without the prior written consent of Clarivate Analytics.